drugset
Drugs / Tegavivint
last change 19 days ago re-read 9 days ago

Tegavivint

also known as BC-2059

Small molecule targets TBL1X via inhibition

Developed for
colorectal carcinoma · desmoid tumor · diffuse large B-cell lymphoma activated B-cell type · diffuse large B-cell lymphoma germinal center B-cell type · endometrial carcinoma · Ewing sarcoma · hepatoblastoma · hepatocellular carcinoma
+14 more · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · high-grade B-cell lymphoma double-hit/triple-hit · leukemia · melanoma · neuroblastoma · non-Hodgkin lymphoma · non-small cell lung carcinoma · osteosarcoma · ovarian carcinoma · pancreatic ductal adenocarcinoma · pediatric osteosarcoma · refractory malignant neoplasm · solid pseudopapillary neoplasm of the pancreas · Wilms tumor
Investigated by
Iterion Therapeutics · Children's Oncology Group · Emory University · HonorHealth Research Institute · Lapo Alinari · M.D. Anderson Cancer Center
+2 more · National Cancer Institute (NCI) · Ohio State University Comprehensive Cancer Center

Trials 8

today NCT07463599 · Ph 1/2 NCT07144254 · Ph 1 NCT05797805 · Ph 1/2 NCT05755087 · Ph 1 NCT04780568 · Ph 1 NCT04851119 · Ph 1/2 NCT04874480 · Ph 1 NCT03459469 · Ph 1
20192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT07144254 Jan 2026 → May 2028 expected pediatric osteosarcoma Emory University Recruiting No outcome recorded
Phase 1 NCT05755087 Mar 2023 → Mar 2028 expected diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, high-grade B-cell lymphoma double-hit/triple-hit Lapo Alinari Recruiting No outcome recorded
Phase 1 NCT04780568 Jan 2022 → Dec 2026 expected non-small cell lung carcinoma Ohio State University Comprehensive Cancer Center Recruiting No outcome recorded
Phase 1 NCT04874480 Sep 2021 → Feb 2027 expected leukemia M.D. Anderson Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT03459469 Jul 2018 → May 2022 desmoid tumor Iterion Therapeutics Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT07463599 Feb 2026 → Jan 2029 expected colorectal carcinoma HonorHealth Research Institute Recruiting No outcome recorded
Phase 1/2 NCT05797805 Sep 2023 → May 2026 overdue hepatocellular carcinoma Iterion Therapeutics Recruiting No outcome recorded
Phase 1/2 NCT04851119 Nov 2021 → Jun 2028 expected Ewing sarcoma, Wilms tumor, colorectal carcinoma, desmoid tumor +10 Children's Oncology Group Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2026-09-22 Iterion Therapeutics Results Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer iteriontherapeutics.com ↗
2022-10-18 Iterion Therapeutics Results Iterion Therapeutics Announces Results from Preclinical study of Tegavivint iteriontherapeutics.com ↗
Tegavivint therapy reduced tumor growth and increased T-lymphocyte infiltration in beta-catenin activated hepatocellular carcinoma models
2022-06-01 Iterion Therapeutics Results Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting iteriontherapeutics.com ↗
Data indicated an objective response rate of 25% in patients with desmoid tumors at the recommended Phase 2 dose
2021-04-12 Iterion Therapeutics Results Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors iteriontherapeutics.com ↗
Data from patients treated in the dose expansion portion of the trial reaffirmed Tegavivint's safety at the RP2D level.

All press releases naming this drug 15 releases

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Tegavivint ClinicalTrials.gov intervention name — accepted as the source's own label NCT07463599 ↗
7

NCT04851119 ↗

NCT03459469 ↗

NCT04874480 ↗

NCT05797805 ↗

NCT05755087 ↗

NCT04780568 ↗

NCT07144254 ↗
Known as BC-2059 ChEMBL registry synonym — accepted as the source's own label CHEMBL3601411 ↗
Action Inhibit “The TBL1 Inhibitor, Tegavivint (BC2059)” NCT05797805 ↗
Modality Small molecule “Tegavivint is a first-in-class small molecule” NCT07144254 ↗
Route Intravenous “Tegavivint administered intravenously” NCT03459469 ↗
Target TBL1 “Tegavivint is a first-in-class chemical inhibitor that interferes with the binding of Transducin beta-like protein 1 (TBL1) to beta-catenin.” NCT07463599 ↗